News | May 13, 2021
COVAXIN phase II/III clinical trial approved for 2-18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Essential medicines were made available to more than 150 countries around the world during the pandemic
Acquisition of A&C expands Aceto’s Western manufacturing footprint
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The government has taken all the effective measures to make healthcare affordable
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
